ERYTHROPOIETIN (Epo) is secreted from the kidneys in response to reduced blood oxygen availability and predominantly acts to increase the number of erythrocytes released from the bone marrow (30) . Treatment with recombinant human Epo (rHuEpo) or an erythropoiesis-stimulating agent (ESA) increases hematocrit and improves aerobic exercise capacity (57) . Epo receptors are also expressed in tissues other than the bone marrow (19 -21, 28, 29, 35, 39, 40, 49) , and nonhematological effects of Epo have been suggested. Epo and endurance training both stimulate mitochondrial biogenesis, a shift in skeletal muscle from a fast glycolytic to a slower oxidative phenotype, and improve aerobic exercise capacity (6, 7, 24, 57) .
Epo treatment to rats leads to a significant increase in the activity of oxidative enzymes (7) , and overexpression of Epo in mice stimulates fat oxidation and expression of genes involved in lipid metabolism, thermogenesis, and inflammation (17) . rHuEpo acutely increases resting energy expenditure (REE) and tends to increase fat oxidation in healthy human subjects (8) . Furthermore, rHuEpo treatment improves insulin sensitivity and dyslipidemia in patients with end-stage renal disease (4, 26, 31-33, 38, 55, 58) . The underlying mechanisms are uncertain but do not seem to be accounted for by correction of anemia (55, 58) .
Endurance training, on the other hand, induces physiological adaptations that eventually improve muscle function and exercise performance. Substrate metabolism is altered with increased muscle glycogen stores and increased fat oxidation and a shift toward a more oxidative phenotype with a larger proportion of type I fibers and increased capillary and mitochondrial density (9) . Endurance training further improves insulin sensitivity in skeletal muscle via numerous mechanisms (16) .
The combined effects of endurance training and ESA treatment on energy homeostasis and metabolism have so far not been investigated in humans. We hypothesized that a larger oxygen supply to the working muscles would enhance the response to training. This information would add to our understanding of exercise physiology and could have clinical implications for patients receiving ESA treatment.
In the present study we therefore investigated the effects of prolonged ESA treatment, endurance training, and a combination hereof on whole body substrate metabolism and insulin sensitivity in healthy human subjects.
METHODS
Subjects. Thirty-eight healthy, young, untrained men, all nonsmokers, were included after receiving oral and written information, and giving written informed consent to participate, in accordance with the Declaration of Helsinki. The study was approved by the Local Human Ethical Committee of Central Denmark Region (M-20110035) and registered at www.clinicaltrails.gov with the clinical trial number NCT01320449.
Maximal oxygen uptake (V O2max) was measured before study start, and only subjects with an oxygen uptake Ͻ50 ml·min Ϫ1 ·kg Ϫ1 were included (moderate to low oxygen uptake). In addition, each participant underwent a physical examination and electrocardiogram measurements. Additional inclusion criteria included: age between 18 and 35 yr, body mass index (BMI) between 18 and 29 kg/m 2 , normal blood pressure Ͻ135/85 mmHg, and a hematocrit Ͻ45%.
Experimental design. In a parallel design, the subjects were randomized to the following four experimental groups: 1) sedentary and placebo treatment (n ϭ 9), 2) sedentary and ESA treatment (n ϭ 9), 3) endurance training and placebo treatment (n ϭ 10), and 4) endurance training and ESA treatment (n ϭ 10). Two participants in the training-ESA group were excluded, one due to a groin injury and one due to poor compliance, leaving the training-ESA group with only eight participants.
The subjects were in a single-blinded manner treated with either ESA (Darbepoietin-␣, Aranesp; Amgen, Thousand Oaks, CA) or placebo for 10 wk. ESA was administered subcutaneously one time weekly at a dose of 40 g for the first 3 wk and 20 g for the remaining 7 wk. However, the first three and four participants in the ESA group and training-ESA group, respectively, were treated two times weekly for the first 3 wk. This led to a larger increase in hematocrit than expected (up to 50 -54%), and the number of injections was therefore reduced to one time weekly. To keep the hematocrit value below 55%, some subjects (n ϭ 9) were switched to placebo injections on a few occasions. Hematocrit was measured weekly throughout the study. The subjects were supplemented with 100 mg iron orally/day (Ferrosulfat, Ferro Duretter; GlaxoSmithKline, Brentford, UK) from 1 wk before the treatment until the end of the study.
Endurance training was supervised and consisted of biking on an indoor ergometer. The subjects performed three training sessions per week; each training session consisted of 5 min warm up, a main set, and 5 min cool down. Each of these three main sets was performed one time weekly: 1) 40 min, 2) 2 ϫ 20 min (5 min easy biking in between), and 3) 8 ϫ 5 min (1 min easy biking in between). All sets were performed with the maximal amount of watt possible, on average 65% of wattmax. Two wattmax tests were performed during the 10 wk of training (weeks 4 and 8) to optimally target the amount of watt at which the training should be performed. The last training session was performed ϳ60 h before the posttests after 10 wk of training to avoid any potential acute exercise effects.
On the day of the metabolic examination, the subjects arrived by taxi to the clinical research unit after an overnight fast (water intake was allowed). The participants were instructed to refrain from physical activity, alcohol intake, or dietary changes 3 days before the experimental day. Two intravenous catheters were inserted: one in the antecubital vein for infusions and one in a heated dorsal hand vein for sampling of arterialized blood. The experimental day was divided into a "basal" [time (t) ϭ 0 -240 min] and a "clamp" period (t ϭ 240 -360 min). Unless stated otherwise, blood analysis referred to as basal represents the mean of three consecutive measurements between t ϭ 210 and t ϭ 240 min, and clamp denotes the mean of three measurements between t ϭ 330 and t ϭ 360 min. Blood was collected before the start of the experiment (t ϭ 0 min) and at the end of the basal (t ϭ 240 min) and clamp (t ϭ 360 min) periods. Blood samples were centrifuged for 10 min at 4°C and 3,800 rpm and stored at minimum Ϫ20°C. Skeletal muscle biopsies were obtained from vastus lateralis muscle under local anesthesia before the start of the experiment and snap-frozen in liquid nitrogen. At the end of each experimental day, a dual-energy X-ray absorptiometry scan was performed (QDR-2000, Hologic Discovery; Hologic, Bedford, MA). The experiment was conducted under thermo neutral conditions (21-23°C). Furthermore, 1-3 days before the experimental day, magnetic resonance imaging (MRI) and MR spectroscopy were performed to assess the volume of the subcutaneous and visceral fat depots as well as intrahepatic and intramyocellular lipid (IMCL) content, respectively.
During the 10-wk study period, the participants were informed not to change their level of physical activity or their dietary habits.
Maximal oxygen uptake. Maximal oxygen uptake was measured before and after the 10-wk intervention period on an ergometer bicycle (Monark Ergomedic 828E; Monark, Varberg, Sweden). Food and liquid intake (except for water) was not allowed 2 h before the test. The test was performed at a constant pedaling rate of 70 rpm, and the first 5 min at 140 watt served as a warm-up to reach a steady state of submaximal work. Hereafter, the workload was increased with 35 watt every minute until exhaustion. The oxygen uptake was measured every 10 s (AMIS 2001; Innovision, Odense, Denmark), and V O2max was calculated as the highest mean of three consecutive measurements. Wattmax is defined as the workload before the last increase plus 35 watt times the percentage of time finished of the last minute (1).
Resting energy expenditure. REE was estimated by indirect calorimetry (Deltatrac monitor; Dantes Instrumentarium, Helsinki, Finland) and was performed for 30 min during both the basal (60 -90 min) and clamp (300 -330 min) periods. The mean values of the last 25 min were used for calculations.
Palmitate turnover. Palmitate turnover was assessed using a 1-h constant infusion of [9,10- 3 H]palmitate (0.3 Ci/min) between 120 and 180 min. Blood samples were drawn at t ϭ 120, 150, 160, 170, and 180 min for measurements of palmitate concentration and specific activity (SA). Steady-state SA was determined during the last 30 min of the infusion in each individual. Plasma palmitate concentration and SA were determined by high-performance liquid chromatography (36) using [ 2 H31]palmitate (Cambridge Isotope Laboratories, Andover, MA) as internal standard as previously described (23) . Systemic palmitate flux (mol/min) was calculated using the [9,10- 3 H]palmitate infusion rate (dpm/min) divided by the steady-state palmitate SA (dpm/mol) (23, 36) .
Hyperinsulinemic-euglycemic clamp. A hyperinsulinemic-euglycemic clamp was performed to assess insulin sensitivity. Insulin was infused from t ϭ 240 to 360 min (0.6 mU·kg Ϫ1 ·min Ϫ1 ; Actrapid; Novo Nordisk, Bagsvaerd, Denmark). Plasma glucose was clamped at ϳ5 mmol/l by adjusting the intravenous infusion rate of 20% glucose according to plasma glucose measurements every 10 min. Insulin sensitivity (M-value) was estimated from the glucose infusion rate (GIR, mg/min): M-value (mg·kg Ϫ1 ·min Ϫ1 ) ϭ GIR/total body wt. The amount of infused glucose required to maintain blood glucose at ϳ5 mmol/l during the clamp, i.e., M-value, reflects peripheral insulin sensitivity. To correct for fluctuations in serum insulin levels, the M-values were divided by serum insulin levels.
1 H-MR spectroscopy and MR imaging. Liver fat fraction (%FF) and Intramyocellular lipid (IMCL) content and visceral as well as subcutaneous fat were measured with MR techniques using a Sigma Excite 1.5 tesla twin-speed scanner (GE Medical Systems). MR spectroscopy of skeletal muscle induced a point-resolved spectroscopy sequence (water suppression; echo time 27 ms; repetition time 3,000 ms) on a 2 ϫ 2 ϫ 2 cm voxel position in the largest cross-sectional area of the tibialis anterior muscle. Full width at half maximum was 13.4 Ϯ 2.2 Hz. The 1 H-MR liver spectroscopy technique used for assessment of FF has previously been described (37) . Full width at half maximum was 13.7 Ϯ 3.3 Hz. The spectra were quantified by using the LCmodel software package (version 6.2; Stephen Provencher) by using a dedicated muscle and liver spectroscopy fitting model. The data processing provided an estimate of the ratio of lipid to water in the tissue within the voxel (48) . MRI assessed the amounts of visceral and subcutaneous fat (body coil; fast-spin echo sequence; echo time: 8.5 ms; repetition time: 600 ms; slice thickness: 8 mm; field of view: 48 cm). Based on repetitive axial slices from the proximal border of the left kidney to the femur neck, data processing was done by using the software package Hippofat (47) .
Gene expression analysis. Five to six milligrams of freeze-dried skeletal muscle were used for RNA extraction using TRIzol (Gibco BRL, Life Technologies, Roskilde, Denmark) and homogenized with one tungsten bead (Qiagen, Germantown, MD) using a Mixer Mill. RNA was quantified by measuring absorbance at 260 and 280 nm with a ratio between RNA and protein Ն1.9 using a NanoDrop 8000 Spectrophotometer (Thermo Scientific Pierce, Waltham, ME). Integrity of the RNA was checked by visual inspection of the two ribosomal RNAs on an agarose gel. cDNA was synthesized using a Verso cDNA kit (catalog no. Ab-1453; Thermo Fischer Scientific) with random hexamer primers. The following primers were used: adenine nucleotide translocator (ANT1): ACTTTGCTAGGACCAG-GTTGGC and ATACAGTCGCCCAGACCATGGAAC, uncoupling protein 2 (UCP2): CCTCATGACAGATGACCTCC and TG-TATCTCGTCTTGACCACG, peroxisome proliferator-activated receptor-␥ coactivator-1␣ (PGC-1␣): TTGAAGAGCGCCGTGTGATT and TGTCTCCATCATCCCGCAGAT, and for ␤2-microglobulin: GAGGCTATCCAGCGTACTCC and AATGTCGGATGGAT-GAAACCC. Real-time quantifications of target gene expressions to ␤2-microglobulin mRNA (housekeeping gene) were performed using a SYBR-Green real-time PCR assay and an ICycler from Bio-Rad. The PCR reactions were performed in duplicate using a KAPA SYBR FAST qPCR Kit (Kapa Biosystems, Woburn, MA) in a LightCycler 480 (Roche Applied Science, Basel, Switzerland) using the following protocol: one step at 95°C for 3 min, then 95°C for 10 s, 60°C for 20 s, and 72°C for 10 s and, finally, to ensure against primer-dimer generation, a melting curve analysis was performed. The increase in fluorescence was measured in real time during the extension step. The relative gene expression was estimated using the default "Advanced Relative Quantification" mode of the software version LCS 480 1.5.0.39 (Roche Applied Science), and specificity of the amplification was checked by a melting temperature analysis.
Western blot analyses. Proteins were purified from freeze-dried skeletal muscle biopsies (ϳ8 mg) by homogenization in homogenization buffer [20 mM Tris, 50 mM NaCl, 50 mM NaF, 5 mM tetrasodium pyrophosphate, 270 mM sucrose, 1% (vol/vol) Triton X-100, 2 mM DTT, and Proteinase inhibitor cocktail (Complete, EDTA-free; Roche Diagnostics, Indianapolis, IN)] on a Precellys 24 (Bertin Technologies, Montigny-le-Bretonneux, France). The samples were gently swirled at 4°C for 15 min, before being centrifuged at 13,000 rpm at 4°C for 20 min. The supernatant was collected, frozen in liquid nitrogen, and stored at Ϫ80°C until further analysis. Protein concentrations were determined by the Bradford assay.
In short, Western blotting was performed as follows: ϳ20 g protein were loaded on a 12% SDS gel (Criterion TGX stain-free gels; Bio-Rad, Hercules, CA), followed by electro blotting onto a PVDF membrane. These stain-free gels allow for the detection of total protein content; a trihalo compound reacts with tryptophan residues in an ultraviolet-induced reaction and produces fluorescence. Therefore, a picture of the membrane was taken for total protein assessment. Membranes were blocked with 2.5% skimmed milk for 2 h before the primary antibody was added and incubated overnight at 4°C. The following primary antibodies were used: GLUT4 (no. 07-1404; Millipore, Billerica, MA) and cytochrome c (no. 4272; Cell Signaling Technology, Danvers, MA). Following several washes, the membrane was incubated with the secondary antibody (donkey-anti-rabbit IgG, no. NA934; Amersham, GE Healthcare) for 1 h at room temperature. Proteins were visualized by a chemiluminescence detection system (Super signal dura extended duration substrate; Pierce).
Blood analysis. Plasma glucose was measured immediately after collection on an YSI 2700 Select (YSI Life Sciences, Yellow Springs, OH). Free fatty acids (FFA) were analyzed by a commercially available kit [intra-assay coefficient of variation (CV) 2-4% and interassay CV 3-6%, detection limit 0.02 mmol/l] (Wako Chemicals, Neuss, Germany). Serum iron, high-density lipoprotein (HDL), lowdensity lipoprotein (LDL), cholesterol, triglyceride, and thyroid-stimulating hormone (TSH) were measured on a Cobas 6000 (Roche Applied Sciences). Hemoglobin and erythrocytes were measured on a Sysmex (Sysmex, Ballerup, Denmark). HbA1C was measured on a Tosoh (Medinor, Brøndby, Denmark). Insulin levels were measured by a commercial time-resolved immunoflourometric assay (intra-assay CV 3.4% and interassay CV 3.8%) (Auto DELFIA; PerkinElmer, Turku, Finland). Total insulin-like growth factor-I (IGF-I) was measured by an IDS iSYS IGF-I kit (IS-3900) (IDS Immune Diagnostic Systems, Boldon, UK).
Statistics. One-way ANOVA was used to assess differences in anthropometric data between the four experimental groups. A twoway ANOVA with training and ESA as factors was used to access percentage changes over the 10 wk in liver and intramyocellular fat content and the amount of visceral and subcutaneous fat tissue. A three-way ANOVA with repeated measurements was used to test differences in body composition, V O2max, wattmax, hematological changes, insulin sensitivity, fasting glucose, mRNA data, Western blot data, and palmitate data. The factors were training, ESA, and time (0 -10 wk). REE, insulin, and FFA values were analyzed using a repeated-measurement ANOVA (PROC MIXED in SAS) formulated as a mixed-effects model with training, ESA, basal/clamp, and time (0 -10 wk) along with all interactions between the four as fixed effects. Subject, the interaction between subject and week, and the interaction between subject and time were considered as random effects. Pairwise comparisons between groups, time (0 vs. 10 wk), and basal/clamp were performed when appropriate. Furthermore, to evaluate if the amount of FFM affected REE, FFM was included in the ANOVA as a covariate. Normality of all data was checked by QQ-plots, and plots of residuals vs. the fitted values and data were log-transformed when appropriate. The correlation between delta changes in REE and UCP2 were also calculated. The level of significance was set to P Ͻ 0.05. Results are presented as means Ϯ SE for normally distributed data and as estimates of the median (95% confidence interval) for nonnormally distributed data. Statistical analyses were made in STATA version 12 (StataCorp, Collage Station, TX) or SAS version 9.3 (SAS Institute, Cary, NC). Graphical presentations were made in SigmaPlot version 11.0 (Systat Software, San Jose, CA).
RESULTS

Study participants.
There were no significant differences in anthropometric characteristics between the four experimental groups, except for a small difference in mean age (P ϭ 0.046) ( Table 1) .
Treatment. For safety reasons, hemoglobin and hematocrit were measured, both of which increased significantly in the two groups treated with ESA (overall ESA effect P Ͻ 0.001). Iron status did not change significantly throughout the study (P ϭ 0.299) ( Table 2) .
Oxygen uptake and training effects. Compliance (no. of completed training sessions out of 30 possible) in both training groups was for all subjects Ͼ92%, with an average of 97 and 98% in the training-placebo and training-ESA groups, respectively. Training and ESA treatment increased V O 2max significantly after 10 wk (time effect P Ͻ 0.001), but there was no statistically significant additive effect of combining training with ESA treatment (Table 2) .
Body composition and lipid storage. Total body fat was significantly reduced (17.9 vs. 16.6%, P ϭ 0.003) after 10 wk in the training-placebo group (Table 3) . No significant changes were found in BMI or fat-free mass (FFM). Furthermore, the amount of visceral and subcutaneous fat tissue did not change significantly during the 10 wk neither in response to either ESA or training. The percent change in %FF over the intervention period was significantly different between groups (P ϭ 0.017). An overall effect of ESA was found (P ϭ 0.025) with a significant difference between the sedentary-placebo and sedentary-ESA groups (P ϭ 0.003), demonstrating that ESA increases hepatic %FF (Table 3) . Furthermore, a significantly higher hepatic %FF was recorded after the intervention period in the sedentary-ESA compared with the training-placebo (P ϭ 0.015) and training-ESA (P ϭ 0.021) groups (Table 3) . IMCL tended to increase after training in general (P ϭ 0.087), and the increase in the placebo-training group tended to be higher than the sedentary-placebo group (P ϭ 0.054) ( Table 3) .
Insulin sensitivity. Insulin sensitivity (M-value) increased significantly both in the training-placebo (P Ͻ 0.001) and training-ESA (P ϭ 0.002) groups. However, serum insulin levels differed significantly between groups during the clamp (Table 4 and Fig. 1) , even though the insulin infusion rate was dosed according to body weight. To correct for this, insulin sensitivity was expressed as M-value/serum-insulin. Insulin sensitivity, expressed as M-value/insulin levels, increased significantly after 10 wk in the training-placebo group (P ϭ 0.011) and tended to increase in the training-ESA group (P ϭ 0.054) (Fig. 1) . These changes were not accompanied by changes in fasting glucose levels (Table 4) or Hb A1c (data not shown). However, skeletal muscle content of GLUT4 was significantly increased after 10 wk in both training groups (training effect P ϭ 0.011) (Fig. 1). Resting energy expenditure. REE increased significantly in the basal period after 10 wk of ESA treatment (P ϭ 0.003) (Fig. 2) . Moreover, REE was significantly higher in the sedentary-ESA group at week 10 compared with the sedentaryplacebo group (P ϭ 0.010). Furthermore, REE significantly increased in the two training groups after 10 wk during the basal period (training-placebo: P ϭ 0.019; training-ESA: P ϭ 0.005) and during the clamp period (training-placebo: P ϭ 0.034; training-ESA: P ϭ 0.009). No additive effects of ESA and training were found (Fig. 2) . Including FFM as a covariate in the REE analysis did not change the results. Additional predictors of REE, including thyroid function (serum TSH levels), the expression of UCP1 and UCP2, and ANT1 in skeletal muscle, were also measured. TSH levels did not change significantly during the study. A significant ESA effect over time (P ϭ 0.035) with an increase from baseline was found for UCP2 mRNA levels in skeletal muscle in the sedentary-ESA group and in the combined training-ESA group (P ϭ 0.05 and P ϭ 0.005, respectively) (Fig. 3) . No correlation between changes in REE and UCP2 was found (P ϭ 0.322). ANT1 expression levels did not change significantly throughout the study, and UCP1 levels were below the detection limit. Cytochrome c levels in skeletal muscle significantly increased in response to training alone (P Ͻ 0.001) but not to ESA treatment alone (P ϭ 0.200); moreover, ESA blunted the training-induced increase in cytochrome c in the combined training-ESA group (Fig. 3) . The PGC-1␣ mRNA levels did not change significantly over time in any of the groups (Fig. 3) .
Fat metabolism. Serum FFA levels at baseline in the training-placebo group were significantly higher compared with sedentary-placebo (P ϭ 0.003) and training-ESA (P ϭ 0.008) Data are expressed as means Ϯ SE; n, no. of subjects. ESA, erythropoiesis-stimulating agent; BMI, body mass index. Shown are anthropometric data at baseline for all experimental groups; sedentary-placebo, sedentary-ESA, training-placebo, and training-ESA. Significant interaction *P Ͻ 0.05; different from sedentary-placebo and training-ESA #P Ͻ 0.05.
Table 2. Maximal oxygen uptake and treatment data
Sedentary-Placebo (n ϭ 9)
Sedentary-ESA (n ϭ 9) Training-Placebo (n ϭ 10) Training-ESA (n ϭ 8) Data are expressed as means Ϯ SE or median [95% (CI) confidence interval]; n, no. of subjects. V O2max, maximal oxygen uptake; EVF, erythrocyte volume fraction. Effects of 10 weeks of ESA treatment and/or aerobic training on V O2max and serum hematocrit, erythrocyte, and iron levels. V O2max is presented both in l/min and ml · min Ϫ1 · kg
Ϫ1
. Difference between baseline and 10 wk within group, ***P Ͻ 0.001; different from 10 wk sedentary-placebo, #P Ͻ 0.05, ##P Ͻ 0.01, ###P Ͻ 0.001; different from baseline sedentary-placebo, $P Ͻ 0.05, $$P Ͻ 0.01, $$$P Ͻ 0.001; different from 10 wk training-placebo, § § §P Ͻ 0.001. groups (Fig. 4) . Serum FFA levels increased significantly after ESA treatment (P ϭ 0.005) and decreased significantly after 10 wk of training (P ϭ 0.013), with no significant change in FFA levels in the training-ESA group (Fig. 4) . The same pattern was also found for serum palmitate concentrations, although a significant decrease was only found in the training-placebo group (P ϭ 0.016) (Fig. 4) . A small but significant difference in palmitate flux (P ϭ 0.048) was found at baseline between groups (Fig. 4) . Endurance training for 10 wk reduced palmitate flux compared with baseline in the training-placebo (P ϭ 0.036) and training-ESA (P Ͻ 0.001) groups. No significant effect of ESA treatment alone on palmitate flux was found (Fig. 4) . FFA levels were almost completely suppressed during the clamp, with an overall significant effect of the clamp (P Ͻ 0.001) ( Table 4) . Plasma HDL, triglyceride, and cholesterol did not change significantly during the study; however, LDL was significantly lower after 10 wk of combined ESA treatment and training (Table 4) .
DISCUSSION
Our study constitutes the first human study of prolonged effects of ESA treatment and endurance training alone and in combination on energy metabolism and insulin sensitivity. REE increased in response to training and ESA alone and in combination. ESA treatment was accompanied by elevated circulating FFA levels and a significant increase in intrahepatic lipid content. In contrast, training significantly decreased FFA levels and fat percentage and increased insulin sensitivity. These opposing lipolytic effects of ESA and training became neutralized in the combined training-ESA group.
Even though ESA treatment and endurance training constitute two different interventions, they share certain effects such as improved aerobic exercise capacity and a shift in skeletal muscle fiber composition from a fast glycolytic to a slower oxidative phenotype (7, 24, 57) . Both endurance training and ESA treatment for 10 wk induced a significant increase in V O 2max , but no statistical significant additive effects of the two interventions were found. However, the delta increase was slightly larger in the combined group (0.77 l/min) compared with after ESA treatment (0.54 l/min) or aerobic training (0.58 l/min) alone. The participants in the current study were sedentary at baseline, which may provide a response to training and ESA treatment that differs compared with highly trained individuals.
REE increased in response to both ESA treatment and endurance training without an additive effect. Interestingly, FFM, which is a major predictor of REE, did not change significantly in any of the intervention groups, and the inclusion of FFM as a covariate in the REE analysis did not change the outcome. Based on serum TSH measurements, it is also unlikely that either intervention had an effect on thyroid function.
The calorigenic effects of ESA are in agreement with our previous study in healthy humans where REE increased 3-3.5 h after a bolus of rHuEpo (8) . Thus, REE increases acutely after rHuEpo exposure and remains elevated during prolonged treatment. The same effect is observed in mice, where REE increased after 3 days of Epo treatment (6) . One possible underlying mechanism could be increased energy demand in response to stimulation of erythropoiesis, but this is an unlikely explanation for the acute calorigenic effects (8) . Heat production in skeletal muscle tissue has previously been shown to increase in hemodialysis patients treated with rHuEpo (12). Furthermore, UCP2, which is involved in thermogenesis by inducing a leak of protons over the mitochondrial membrane and subsequent heat production, was upregulated after Epo administration for 1 wk in mice (17) . No upregulation in the expression of UCP mRNA in skeletal muscle was found 1 h after an acute bolus of rHuEpo in healthy humans (8) . In the current study, however, prolonged treatment with ESA led to an increase in UCP2 mRNA levels in both groups treated with ESA (Fig. 3) , although no significant correlation between delta changes in REE and UCP2 was found. Thus, increased heat production might partly account for the observed increase in REE levels after ESA treatment, but additional hitherto unknown factors are also likely to con- tribute. There was no significant effect of ESA on cytochrome c protein or PGC-1␣ mRNA levels, indicating that ESA does not stimulate mitochondrial biogenesis. By contrast, ESA seemed to blunt the training-induced increase in cytochrome c, leaving the training-ESA group with unaltered cytochrome c levels. Thus, Epo or the increased oxygen availability possibly suppresses the stimuli for mitochondrial biogenesis induced by aerobic training. In support hereof, a decrease in cytochrome c and PGC-1␣ protein levels has recently been found in rats treated with Epo for 3 wk in gastrocnemius but not soleus muscle (34) . Furthermore, prolonged exposure to sustained hypoxia, presumably associated with high endogenous serum Epo levels, led to a suppression of mitochondrial biogenesis and loss of subsarcolemmal mitochondria (27) . In contradiction, increased mitochondrial biogenesis has been shown in response to Epo treatment in mice cardiac tissue (6).
REE also increased in response to endurance training in the current study. Endurance training stimulates mitochondrial biogenesis, and studies have shown that basal rates of substrate oxidation in the tricarboxylic acid cycle are increased while muscle energy production (ATP synthesis) is unaltered, which indicates increased mitochondrial uncoupling (2) . This H ϩ leak can be explained by increased levels of ANT and UCP and may eventually lead to an increase in REE. As opposed to ESA treatment, aerobic training alone did not alter ANT1 or UCP2 gene expression. In the current study, skeletal muscle cytochrome c content, but not PGC-1␣ mRNA levels, was significantly increased in response to training alone. It is well known that acute exercise leads to increases in PGC-1␣ mRNA levels, which induces mitochondrial biogenesis and increases cytochrome c protein content (41) . This acute upregulation in PGC-1␣ mRNA levels returns to resting levels within 24 h (43); thus, in the current study where the biopsies were col- lected Ͼ60 h after the last exercise bout, only changes in the basal levels of mRNA can be detected. One-legged knee extensor exercise training for 4 wk has previously been shown not to affect basal PGC-1␣ mRNA levels (43). Other possible mechanisms by which aerobic exercise could increase REE include activation of thyroid function (unaltered in the current study) and the sympathetic nervous system and by increased substrate flux and elevated protein synthesis (45) . Unaltered REE is found in some studies after endurance training in previously untrained subjects (5, 50, 59) , and also when comparing highly trained subjects with sedentary controls with matching FFM (2, 52) . However, in one study, REE was higher in a group of elite cross-country skiers compared with sedentary subjects matched for FFM (54) , and a significant correlation between V O 2max and resting metabolic rate has been shown (46) . The reason for these discrepancies is currently unknown. Even though increased aerobic capacity is normally correlated with increased insulin sensitivity (3), in the current study, insulin sensitivity was only significantly increased in the training groups, whereas no effect of ESA treatment was found. These discrepancies can be explained by the very different physiological ways whereby V O 2max increases in response to ESA treatment (increased oxygen supply) and aerobic training (muscular adaptations). In support hereof, a significantly increased GLUT4 content in skeletal muscle tissue was found in response to training but not to ESA treatment alone. Although insulin infusion rates were dosed according to body weight, significant differences in serum insulin levels were found between groups during the clamp in the sense that rHuEpo treatment led to significantly higher insulin levels during the clamp at 10 wk. It is unlikely that endogenous insulin secretion was stimulated during these euglycemic conditions. Plasma clearance of infused insulin is mainly renal, as opposed to endogenous insulin, which to a major extent is subjected to a first-pass metabolism in the liver, and occurs by both glomerular filtration and proximal tubular reabsorption and degradation (11) . Prolonged treatment with rHuEpo decreases proximal tubular reabsorption and glomerular filtration rate (42) . This could explain the slower clearance of insulin during the clamp in the ESA-treated subjects. When correcting the Mvalue for serum insulin levels during the final period of the clamp, a significant improvement in insulin sensitivity was found only in the training-placebo group. The increase in the training-ESA group, however, almost reached statistical sig- Fig. 1 . Insulin sensitivity. The effects of 10 wk of erythropoiesis-stimulating agent (ESA) treatment and/or aerobic training on peripheral insulin sensitivity measured by a hyperinsulinemic-euglycemic clamp, serum insulin levels during the clamp, and skeletal muscle GLUT4 content. Because of significant differences in serum insulin levels during the clamp, insulin sensitivity is presented both as the M-value and the M-value corrected for insulin levels. The experimental groups are as follows: SP, sedentary-placebo; SE, sedentary-ESA; TP, training-placebo; TE, training-ESA. Data are shown as means Ϯ SE, and significant differences are marked (*P Ͻ 0.05, **P Ͻ 0.01, and ***P Ͻ 0.001). Insulin sensitivity expressed as M-value (A), serum insulin levels during the clamp (B), insulin sensitivity expressed as M-value/insulin level (C), and skeletal muscle GLUT4 content per total protein content in lane (loading control), representative blots are shown for each group (D).
nificance (P ϭ 0.054) and is thus probably a result of low statistical power.
Our observation that prolonged ESA treatment alone did not affect insulin sensitivity is in line with data obtained after acute rHuEpo treatment in healthy human subjects (8) . However, mechanistic studies on this subject in mice are conflicting, reporting either unchanged (17) or improved (25) insulin sensitivity. Studies in insulin-resistant patients on hemodialysis demonstrate improvements in insulin sensitivity after treatment with rHuEpo to a level comparable to healthy controls (31) (32) (33) 55) , which, however, may be accounted for by secondary effects such as increased physical activity and alterations in body composition. In the current study, a small nonsignificant increase in total skeletal muscle GLUT4 content after ESA treatment and a tendency to an additive effect of ESA treatment and training on GLUT4 content was found. Of note, these changes did not lead to significantly altered insulin sensitivity. GLUT4 content has not previously been measured after prolonged ESA treatment in healthy subjects, and no direct link between Epo and GLUT4 has so far been established. Whether this represents a compensatory response to ESA treatment merits consideration, and it would also be of interest to study if Epo impact the translocation and function of GLUT4 in skeletal muscle.
Endurance training is also known to improve insulin sensitivity and glucose homeostasis in both healthy and insulinresistant subjects (10, 14, 15, 53) . These beneficial effects seem only partly to be due to improved insulin action but rather reflect adaptations in postreceptor events and hemodynamic actions of insulin (3, 10, 14, 15) .
Another beneficial effect of increased aerobic fitness, partly mediated by the increased insulin sensitivity, is a shift in substrate metabolism in favor of increased fat oxidation during submaximal exercise (3, 18) . In the current study, training decreased FFA levels and palmitate flux (rate of appearance in the blood) at rest while ESA treatment induced the opposite pattern, and these opposing effects seemed to become neutralized when combining training and ESA treatment.
Elevated serum FFA levels in concomitance with accumulation of intrahepatic lipid are central features of the metabolic syndrome and causally linked to insulin resistance. The FF% of liver increased significantly from 1.7 to 2.9% after ESA treatment and therefore remains within the normal range (Ͻ5.5% of liver volume) (56) . FF% was unchanged when ESA treatment was combined with aerobic treatment. A plausible explanation for this phenomenon could be that training increased fat oxidation, thereby preventing accumulation of excessive fat in the liver. In the present study insulin sensitivity did not deteriorate during ESA treatment, but the observation that serum FFA levels and intrahepatic lipid content increase during ESA treatment in contrast to exercise is noteworthy and merits further research.
Training alone significantly decreased lipolysis by decreasing palmitate flux, resulting in lowered circulating FFA and palmitate levels at rest (Fig. 3) . This is in accordance with a previous study where endurance biking for 10 wk induced a tendency to lower resting FFA concentrations without a significant change in turnover (13) . Furthermore, we recorded a significant decrease in palmitate flux and increased insulin sensitivity in the training groups. Palmitate flux is negatively regulated by insulin, and an increase in insulin sensitivity increases glucose rate of disappearance from the blood and inhibits lipolysis (22) . The improvement in insulin sensitivity was accompanied by lower insulin levels at 10 wk compared with baseline (not statistically significant), in concomitance with suppression of serum FFA levels and a decreased palmitate flux. A tendency to increased IMCL content and a significant decrease in fat percentage were also found, both recognized effects of aerobic exercise training (13, 51) .
Food intake was not controlled for in the current study, but the participants were instructed not to change their dietary or physical habits throughout the study. Body weight and composition did not change throughout the intervention period, except for a small decrease in fat percentage in the trainingplacebo group, which is in accordance with a previous study Resting energy expenditure (REE). Changes in REE in relation to 10 wk of ESA treatment and/or aerobic training, both during a basal period (basal) and a hyperinsulinemic-euglycemic clamp (clamp). Results are shown for all experimental groups. Data for REE are shown as means Ϯ SE, and significant differences are marked (*P Ͻ 0.05 and **P Ͻ 0.01). (13) . Body composition did not change in response to the ESA treatment, which is in accordance with a previous human study (44) .
In conclusion, ESA treatment and endurance training both induce a significant increase in REE. The mechanisms underlying the calorigenic effects of acute and prolonged rHuEpo/ ESA treatment remain uncertain, but increased heat production as a consequence of uncoupling of oxidative phosphorylation is a possible candidate. Treatment with ESA also increased circulating FFA levels and the intrahepatic content of lipids, which suggest direct effects of Epo on fatty acid metabolism. Taken together, our data do not support an additive or synergistic effect of Epo and endurance training on insulin sensitivity, body composition, or aerobic exercise capacity in previously untrained men. The mechanisms underlying the ability of ESA treatment to elevate serum FFA levels Representative blots are shown for each group. Data are shown as means Ϯ SE, and significant differences are marked (*P Ͻ 0.05 and ***P Ͻ 0.001). Fig. 4 . Fat metabolism. Changes in fat metabolism measured as changes in serum free fatty acid (FFA) and palmitate levels as well as palmitate flux during the basal period before the hyperinsulinemic clamp, in all experimental groups. Data for serum FFA levels (A), serum palmitate concentrations (B), and palmitate flux (C) are shown. Data are shown as means Ϯ SE, and significant differences are marked (*P Ͻ 0.05, **P Ͻ 0.01, and ***P Ͻ 0.001). and intrahepatic lipid content, which was abrogated by concomitant exercise, remain unknown and merit further research.
